Please wait a minute...
医药导报  2019, Vol. 38 Issue (6): 775-779    DOI: 10.3870/j.issn.1004-0781.2019.06.020
  本期目录 | 过刊浏览 | 高级检索 |
半乳糖介导姜黄素牛血清白蛋白纳米粒的制备及质量评价*
张云(),林毅鸿,叶扬扬,艾凤伟()
徐州医科大学药学院,徐州 221004
Preparation and Characterization of Galactose-mediated Curcumin Bovine Berum Albumin Nanoparticles
Yun ZHANG(),Yihong LIN,Yangyang YE,Fengwei AI()
School of Pharmacy, Xuzhou Medical University, Xuzhou 221004, China
全文: PDF(1848 KB)   HTML
输出: BibTeX | EndNote (RIS)      
摘要 

目的 建立去溶剂法制备半乳糖介导的姜黄素白蛋白纳米粒,并考察其理化性质及体外释药特性。方法 以半乳糖修饰的牛血清白蛋白作为载体材料,姜黄素作为模型药物,采用去溶剂法制备姜黄素半乳糖化白蛋白纳米粒,单因素考察优化处方工艺,采用激光纳米粒度仪对其粒径和Zeta电位进行测定;超速离心法测定包封率及载药量;透析法考察其体外释药特性。结果 根据优化处方工艺制备的白蛋白纳米粒外观呈圆形或类圆形,粒径分布为(267.1±78.3) nm,Zeta电位为-40~-50 mV;包封率为79.4%,载药量为3.7%;姜黄素纳米粒在 8 h释药量为20%,48 h释药量>80%。结论 去溶剂法制备的姜黄素纳米粒具有良好的理化性质和释药性能,提高药物的稳定性,可显著提高药物释放速率,提高生物利用度。

服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
张云
林毅鸿
叶扬扬
艾凤伟
关键词 牛血清白蛋白半乳糖纳米粒姜黄素去溶剂法    
Abstract

Objective To prepare galactosylated bovine serum albumin nanoparticles (Gal-BSA NPs) of curcumin by desolvation method, and to investigate its physicochemical properties and in vitro release characteristics. Methods Gal-BSA NPs were prepared by emulsion solvent evaporation method, and the preparation processes was optimized. Its size and Zeta potential were measured by Laser size and Zeta potential instrument. Entrapment efficiency and drug loading were measured by ultracentrifugation. The in vitro release characteristics were investigated by dialysis method. Results According to the preparation of the formulation and process optimization, the appearance of Gal-BSA NPs prove to be round or oval, particle size distribution was (267.1±78.3) nm, Zeta potential was -40 to -50 mV. Entrapment efficiency was 79.4%, and drug loading was 3.7%. Gal-BSA NPs release 20% at 8 h and >80% at 48 h. Conclusion Solvent evaporation method can successfully prepare Gal-BSA NPs, and shows good physical and chemical properties and release properties, improve the stability of the drug, and can prolong the drug release rate and improve the bioavailability.

Key wordsBovine serumalbumin    Galactosylated    Nanoparticles    Curcumin    Desolvation technique
收稿日期: 2018-02-06      出版日期: 2019-06-11
基金资助:*徐州市科技计划项目(KC14SH077),江苏省大学生创新创业训练计划项目(201710313056X)
引用本文:   
张云,林毅鸿,叶扬扬,艾凤伟. 半乳糖介导姜黄素牛血清白蛋白纳米粒的制备及质量评价*[J]. 医药导报, 2019, 38(6): 775-779.
Yun ZHANG,Yihong LIN,Yangyang YE,Fengwei AI. Preparation and Characterization of Galactose-mediated Curcumin Bovine Berum Albumin Nanoparticles. Herald of Medicine, 2019, 38(6): 775-779.
链接本文:  
http://www.yydbzz.com/CN/10.3870/j.issn.1004-0781.2019.06.020      或      http://www.yydbzz.com/CN/Y2019/V38/I6/775
图1  BSA(a)、乳糖酸(b)、Gal-BSA(c) 的红外图谱
样品数 pH值 BSA浓度/
(mg·mL-1)
乙醇体积/
mL
粒径/
nm
包封率/
%
1 6 20 5 聚集
2 7 20 5 286.3±103.1 62.7
3 8 20 5 246.3±76.9 64.1
4 8 40 5 386.0±41.7 79.4
5 8 15 5 213.9±76.6 58.1
6 8 30 5 267.1±78.3 78.2
7 8 20 8 304.3±114.1 58.9
8 8 20 10 370.9±179.2 69.5
表1  Gal-BSA NPs的制备影响因素实验结果
图2  Gal-BSA NPs透射电镜、粒径分布及电位
图3  姜黄素与Gal-BSA NPs体外释药曲线
拟合类型 拟合方程 相关系数
(R2)
零级方程 Q=0.016 6t+0.083 6 0.952 3
一级方程 ln(1-Q)=-0.049 7t-0.055 96 0.845 3
Higuchi方程 Q=0.1118t1/2+0.020 1 0.892 8
表2  体外释药模型拟合结果
[1] PANCHAL H D,VRANIZAN K,LEE C Y,et al.Early anti-oxidative and anti-proliferative curcumin effects on neuroglioma cells suggest therapeutic targets[J].Neurochem Res,2008,3(9):1701-1710.
doi: 10.1007/s11064-008-9608-x pmid: 1829998062
[2] 孙永,彭明利.姜黄素及其衍生物在肝脏相关疾病中防治作用的研究进展[J].药学学报,2014,49(11):1483-1490.
[3] 隋菱,郑静彬,蔡国弟,等.姜黄素对四氯化碳诱导大鼠急性肝损害的保护作用[J].中国现代应用药学,2017,34(11):1517-1521.
[4] 李旭炯,刘安,陈云霞,等.姜黄素对肝肺综合征大鼠的保护作用[J].中国临床药理学与治疗学,2017,22(7):738-742.
[5] 徐步远,潘显阁,陈崇别,等.姜黄素对Lewis肺癌小鼠血管内皮成长因子和endostatin表达的影响[J].中国临床药理学与治疗学,2017,22(2):151-154.
[6] UM Y,CHO S,WOO H,et al.Synthesis of curcumin mimics with multidrug resistance reversal activities[J].Bioorg Med Chem,2008,16(7):3608-3615.
doi: 10.1016/j.bmc.2008.02.012
[7] KURIEN B T,SINGH A,MATSUMOTO H,et al.Improving the solubility and pharmacological efficacy of curcumin by heat treatment[J]. Assay Drug Dev Technol,2007,5(4):567-576.
doi: 10.1089/adt.2007.064
[8] WANG Y J,PAN M H,CHENG A L,et al.Stability of curcumin in buffer solutions and characterization of its degradation products[J].J Pharm Biomed Anal,1997,15(12):1867-1876.
doi: 10.1016/S0731-7085(96)02024-9
[9] 陈晓红,迟宗良,秦昆明,等.姜黄素-赖氨酸共晶在无水乙醇中的热力学研究[J].中国现代应用药学,2017,34(6):871-875.
doi: 10.13748/j.cnki.issn1007-7693.2017.06.019
[10] 高会乐,蒋新国.肿瘤靶向递药新策略的研究进展[J].药学学报,2016,51(2):272-280.
[11] 戴东波,尤佳何,雯洁,等.姜黄素聚乙二醇-聚乳酸嵌段共聚物纳米粒的制备及其质量评价[J].中草药,2014,45(2):194-199.
[12] ELZOGHBY A O,SAMY W M,ELGINDY N A.Albumin-based nanoparticles as potential controlled release drug delivery systems[J].J Control Release,2012,157(2):168-182.
doi: 10.1016/j.jconrel.2011.07.031
[13] LI C,ZHANG D,GUO H,et al.Preparation and characteri-zation of galactosylated bovine serum albumin nanoparticles for liver-targeted delivery of oridonin[J].Int J Pharm,2013,448(1):79-86.
doi: 10.1016/j.ijpharm.2013.03.019
[10] GAO S,SUN J,FU D,et al.Preparation,characterization and pharmacokinetic studies of tacrolimus-dimethyl-cyclodextrin inclusion complex-loaded albuminnanoparticles[J].Int J Pharm,2012,4(27):410-416.
[11] 潘艺茗,黄岳山.聚乳酸/聚乙二醇琥珀酸酯-姜黄素纳米粒的制备及体外评价[J].中国组织工程研究,2012,16(3):421-425.
[12] 李然,赵燕娜,王婷,等.基于新型树枝状大分子姜黄素纳米粒的制备及体外释放[J].医药导报,2017,36(5):538-543.
[13] 徐红,张成鸿,关欣,等.槲皮素PLGA-TPGS纳米粒的质量考察[J].医药导报,2017,36(10):1182-1186.
[14] 艾凤伟,庄海涛,凌勇,等.星点设计-效应面法优化青蒿素微囊的制备工艺[J].中成药,2015,37(7):1457-1461.
[1] 张春雷,武艳,李洪志,李玲玉,刘洁婷,柏合,袁晓环. 姜黄素类似物H8对db/db小鼠肝脏炎症因子表达的影响*[J]. 医药导报, 2018, 37(9): 1038-1043.
[2] 霍潘峰,滕亮,胡旭,詹羽姣,徐芳,赵军. 阿尔泰金莲花总黄酮及其荭草素2″-O-β-L-半乳糖苷的提取工艺[J]. 医药导报, 2018, 37(7): 869-873.
[3] 邓艾平,王奕,刘珏,胡振夏,符旭东. 叶酸壳寡糖修饰的聚乳酸-羟基乙酸共聚物纳米粒对耐紫杉醇人卵巢癌细胞增殖的影响[J]. 医药导报, 2018, 37(6): 662-666.
[4] 盛剑勇,杨晓宇,陈佶棠,彭天昊,杨祥良. 胰岛素口服纳米给药系统研究进展[J]. 医药导报, 2018, 37(6): 703-707.
[5] 徐红,高萌,关欣,董浩,董仁超,丛中笑,张成鸿,田燕. 槲皮素PLGA-TPGS纳米粒处方筛选及体外稳定性*[J]. 医药导报, 2018, 37(3): 345-350.
[6] 毛倩,田伟强,丁蔚. 姜黄素纳米脂质体对糖尿病心肌病的预防作用[J]. 医药导报, 2018, 37(11): 1316-1320.
[7] 刘俊香,刘洁婷,唐春银,李玲玉,柏合,袁晓环,张伟,孙丽岩,武艳. 姜黄素对非小细胞肺癌A549细胞的影响*[J]. 医药导报, 2017, 36(8): 865-869.
[8] 魏曼,张宇佳,陈谕园,张楠,郑稳生. 微柱离心-HPLC法测定载左旋多巴聚乙二醇化固体脂质纳米粒的包封率*[J]. 医药导报, 2017, 36(7): 797-800.
[9] 孔玉方,杨毅梅. 纳米佐剂疫苗的特点与应用*[J]. 医药导报, 2017, 36(6): 654-658.
[10] 李然,赵燕娜,王婷,韩美华,王向涛,阎雪莹,郭一飞. 基于新型树枝状大分子姜黄素纳米粒的制备及体外释放*[J]. 医药导报, 2017, 36(5): 538-543.
[11] 赵孝金,李玲玉,李莉,唐春银,李洪志,刘洁婷,张春雷,武艳,袁晓环. 姜黄素及其类似物H8改善db/db小鼠糖脂代谢紊乱*[J]. 医药导报, 2017, 36(12): 1354-1358.
[12] 周开珩,张明. 姜黄素对糖尿病心肌病大鼠心肌细胞凋亡的影响[J]. 医药导报, 2017, 36(11): 1264-1267.
[13] 徐红,张成鸿,关欣,董浩,贾续东,刘长松,高萌,田燕. 槲皮素PLGA-TPGS纳米粒的质量考察*[J]. 医药导报, 2017, 36(10): 1182-1186.
[14] 史琛,傅德皓,郑思维. 汉防己甲素-PLGA纳米粒的制备与体外释放*[J]. 医药导报, 2016, 35(6): 627-631.
[15] 牛筛龙,张兴耐,吴之琳,姚晶晶. 茵陈总黄酮对急性肝损伤大鼠的保护作用[J]. 医药导报, 2016, 35(3): 246-248.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   

通信地址:武汉市蔡甸区中法生态城同济医院专家社区C栋平层《医药导报》编辑部,邮政编码:430199
鄂ICP备07004419号
版权所有:《医药导报》编辑部
网址:www.yydb.cn;www.yydbzz.com
电话:027-69378382,69378383 电子邮箱: yydbzz@163.com
技术支持:北京玛格泰克科技发展有限公司 鄂ICP备09001709号-11